topikal finanstreid kullanım calısması

[bendeniz]

BU KONU TOPİKAL FİNSTREİD İLE SAC DÖKÜLMESİ CALISMASI BİZİM LOSYONLAR İCİN YOL GSOETERİCİ TOPİKAL KULLANIM FAYDALI FAYDASIZMI VS .................................................. ............... Int J Clin Pharmacol Ther. 2014 Oct;52(10):842-9. doi: 10.5414/CP202119.
A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R.
Abstract
OBJECTIVE:
Finasteride, a selective inhibitor of type 2 5-alpha reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet, with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT.
METHODS:
24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined.
RESULTS:
After multiple doses, mean (± SD) finasteride Cmax and AUC0-t corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet. Plasma DHT was reduced by ~ 68 - 75% with the topical solution and by ~ 62 - 72% with the tablet. No relevant changes occurred for plasma testosterone with either treatment. No clinically significant adverse events occurred.
CONCLUSIONS:
A strong and similar inhibition of plasma DHT was found after 1 week of treatment with the topical and tablet finasteride ormulations, albeit finasteride plasma exposure was significantly lower with the topical than with the oral product (p < 0.0001).

[bendeniz]

baska calısma dutastreid
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride.
Münster U1, Hammer S, Blume-Peytavi U, Schäfer-Korting M.
Author information
Abstract
Since the limited knowledge of cutaneous drug metabolism can impair the development of specifically acting topical dermatics and transdermal application systems, the cell-type-specific androgen metabolism in human skin and its inhibition by drugs were investigated. Cultured human foreskin and scalp skin keratinocytes and fibroblasts as well as occipital scalp dermal papilla cells (DPC) were incubated with testosterone 10(-6) and 10(-8)M alone and in the presence of 17alpha-estradiol, 17beta-estradiol or dutasteride for 24 h. Androgens extracted from culture supernatants were subjected to thin-layer chromatography and quantified by beta-counting. In keratinocytes and DPC, dihydrotestosterone (DHT) was only formed to a low extent while androstenedione was the main metabolite. In fibroblasts, DHT formation was pronounced following 10(-8)M testosterone. Dutasteride 10(-8)M completely suppressed 5alpha-dihydro metabolite formation. 17alpha-Estradiol and 17beta-estradiol at nontoxic concentrations decreased 17-ketometabolites. Human skin regulates testosterone action by cell-type-specific activation or deactivation. Effects of 17alpha-estradiol in androgenetic alopecia are not due to 5alpha-reductase inhibition. Dutasteride may be useful in acne and androgenetic alopecia.
Copyright 2003 S. Karger AG, Basel

[bendeniz]

İNSAN TESTİS DHT ETKİSİ e finasterid etkisi.
Castro-Magana M 1 , Angulo E , Fuentes B , Canas bir , Sarrantonio E , Arguello R , Vitollo p .
Yazar bilgileri
Soyut
Biz testis fonksiyon ve 2 yıl için (günde bir kez 10 mg) finasterid ile tedavi edildi erkek tipi kellik ile 22 erkeklerde androjen bazı aracılı olayları (yaş 16-30 yıl) okudu. Hastalar her 3 ayda değerlendirildi. Prostat hacmi endorektal ultrason taramaları altı bireylerde tespit edilmiştir. Serum gonadotropin, prostat spesifik antijen (PSA), ve seks hormon düzeyleri tedavi süresince dorsalde ve periyodik belirlendi. Ondört konular, insan koryonik gonadotropin (hCG), ve salgılatıcı hormon (GnRH) önce ve tedavinin 2 yıl sonra sekiz konularda, tespit edilmiştir gonadotropin gonadotropin yanıt ile gonadal stimülasyonu uygulandı. Finasterid tedavisi serum testosteron düzeyleri (17.2 +/- 2.5 vs 26.3 +/- 1.7 nmol / L) ve dihidrotestosteron bir azalma (artış ile ilişkili olduğu erkek tipi kellik ve prostat büzülme bir düzelme sağladı DHT ) düzeyleri testosteron / belirgin bir artışa neden (1.45 +/- 0.41 vs 0.38 +/- 0.10 nmol / L), DHT oranı. Androstendion serum düzeylerinde anlamlı bir artış (3.67 +/- 0.49 vs 7.05 +/- 0.70 nmol / L) ve östradiol (132 +/- 44 187 +/- 26 pmol / L vs) de not edildi, oysa androstanediol glukuronidi (33.3 +/- 6.4 vs 10.7 +/- 4.5 pmol) ve PSA (1.6 +/- 0.6 vs 0.4 +/- 0.1 ng / ml) anlamlı olarak azalmıştır. Gonadotropin bazal veya uyarılmış seviyelerde değişiklik gözlenmedi. Finasterid tarafından uyarılan tıkanmasından kaynaklanan testosteron metabolizmasının azalması ile, en azından kısmen, açıklanabilir: finasterid tedavisi (16.7 vs 35.5 nmol / L delta) sırasında hCG testosteron yanıt önemli bir artış vardı. Testosteron ve hCG tedavisinden sonra gözlenen oranları estronun estradiole için androstenedion azalması, ancak, oldukça arttırılmış bir 17-ketosteroid redüktaz enzimi aktivitesi ve testosteron üretimi için testis kapasitesinin bir iyileşme olduğunu ima eder.
Sayfalar: 8957695 [PubMed - MEDLINE için dizine]

[bendeniz]

KADINLARDA AGA ANDROGENETİK ALOPESİ CALISMASIGeburtshilfe Frauenheilkd. 1988 Apr;48(4):203-14.
[Hormonal diagnosis in so-called androgenetic alopecia in the female].
[Article in German]
Moltz L.
Abstract
Androgenetic alopecia (a.A.) occurs quite frequently. Up to 79% of women suffer at least temporarily from varying degrees of intermittent diffuse hair loss in the centro-parietal and/or fronto-temporal regions. A.A. is caused by an androgen excess acting on the hair follicle for prolonged periods of time in the presence of a genetic predisposition. However, often hyperandrogenemia cannot be demonstrated in such patients. 125 women with clinically typical a.A. were investigated prospectively under standardized conditions. Patient age ranged from 18 to 68 years (mean +/- SD: 34 +/- 11.6). Atypical uterine bleeding such as menorrhagia, hypermenorrhea and polymenorrhea were found in 69 women. The hair loss varied between 50 and 400 hairs per day (124 +/- 125). Additional signs of hyperandrogenism, i.e. seborrhea (n = 83), acne (n = 52) and hirsutism (n = 28), were often observed. Basal levels of total and free testosterone (T and FT), dihydro-T (DHT) DHEA-sulfate (DS), delta 4-androstendione (A), 17 alpha-hydroxy-progesterone (17P), cortisol (F), progesterone (P), 17 beta-estradiol (E2), sex hormone binding globuline (SHBG), prolactin (PRL), thyreoidea-stimulating hormone (TSH), ferritin (Fe), vitamin B12 (B12) and folat (Fo) were determined by RIA. FT was also measured by equilibrium dialyses. Different methods of determining bound and unbound T were used; their diagnostic value is discussed in detail. In addition, a combined ACTH/TRH-stimulation test was performed in all patients. Pathologic changes of one parameter were detectable in 26.4% of patients, while 67.2% revealed deviations of two or more indices. Excluding clinically relevant borderline values, only 6.4% of patients were without any abnormalities. The incidence rate of pathologic parameters was as follows: FT in % = 52%, Fe = 42%, PRL = 34%, E2 = 34%, FT in pg = 29%, DHT = 28%, SHBG = 26%, TSH = 20.8%, DS = 19%, T = 14%, 17P = 11%, Fo = 7%, A = 6%, F = 6%, B12 = 5%. Group and individual case analyses revealed significant correlations between (1) the levels of the various androgens, PRL and TSH and (2) the E2, SHBG and FT values; these, in turn, were correlated to (3) the occurrence of certain bleeding anomalies (amount, duration, interval) and corresponding ferritin deficiency. Therapy was directed at normalizing the disturbed estrogen-androgen-balance. Using low-dose antiandrogens, estrogens, prolactin suppressants, corticoids, iron-II-preparations as well as estrogen-containing hair lotions hair loss was arrested in 74 of 104 treated women, while regrowth of hair was accomplished in 16 patients. 14 women did not respond to therapy.

[bendeniz]

BİTKİSEL CALISMA Geburtshilfe Frauenheilkd. 1988 Apr;48(4):203-14.
[Hormonal diagnosis in so-called androgenetic alopecia in the female].
[Article in German]
Moltz L.
Abstract
Androgenetic alopecia (a.A.) occurs quite frequently. Up to 79% of women suffer at least temporarily from varying degrees of intermittent diffuse hair loss in the centro-parietal and/or fronto-temporal regions. A.A. is caused by an androgen excess acting on the hair follicle for prolonged periods of time in the presence of a genetic predisposition. However, often hyperandrogenemia cannot be demonstrated in such patients. 125 women with clinically typical a.A. were investigated prospectively under standardized conditions. Patient age ranged from 18 to 68 years (mean +/- SD: 34 +/- 11.6). Atypical uterine bleeding such as menorrhagia, hypermenorrhea and polymenorrhea were found in 69 women. The hair loss varied between 50 and 400 hairs per day (124 +/- 125). Additional signs of hyperandrogenism, i.e. seborrhea (n = 83), acne (n = 52) and hirsutism (n = 28), were often observed. Basal levels of total and free testosterone (T and FT), dihydro-T (DHT) DHEA-sulfate (DS), delta 4-androstendione (A), 17 alpha-hydroxy-progesterone (17P), cortisol (F), progesterone (P), 17 beta-estradiol (E2), sex hormone binding globuline (SHBG), prolactin (PRL), thyreoidea-stimulating hormone (TSH), ferritin (Fe), vitamin B12 (B12) and folat (Fo) were determined by RIA. FT was also measured by equilibrium dialyses. Different methods of determining bound and unbound T were used; their diagnostic value is discussed in detail. In addition, a combined ACTH/TRH-stimulation test was performed in all patients. Pathologic changes of one parameter were detectable in 26.4% of patients, while 67.2% revealed deviations of two or more indices. Excluding clinically relevant borderline values, only 6.4% of patients were without any abnormalities. The incidence rate of pathologic parameters was as follows: FT in % = 52%, Fe = 42%, PRL = 34%, E2 = 34%, FT in pg = 29%, DHT = 28%, SHBG = 26%, TSH = 20.8%, DS = 19%, T = 14%, 17P = 11%, Fo = 7%, A = 6%, F = 6%, B12 = 5%. Group and individual case analyses revealed significant correlations between (1) the levels of the various androgens, PRL and TSH and (2) the E2, SHBG and FT values; these, in turn, were correlated to (3) the occurrence of certain bleeding anomalies (amount, duration, interval) and corresponding ferritin deficiency. Therapy was directed at normalizing the disturbed estrogen-androgen-balance. Using low-dose antiandrogens, estrogens, prolactin suppressants, corticoids, iron-II-preparations as well as estrogen-containing hair lotions hair loss was arrested in 74 of 104 treated women, while regrowth of hair was accomplished in 16 patients. 14 women did not respond to therapy.

[bendeniz]

al bitkici kardes saw palmetto bilimsel calısması
Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
Rossi A, Mari E, Scarno M, Garelli V, Maxia C, Scali E, Iorio A, Carlesimo M.
Abstract
The objective of this open label study is to determine the effectiveness of Serenoa repens in treating male androgenetic alopecia (AGA), by comparing its results with finasteride. For this purpose, we enrolled 100 male patients with clinically diagnosed mild to moderate AGA. One group received Serenoa repens 320 mg every day for 24 months, while the other received finasteride 1 mg every day for the same period. In order to assess the efficacy of the treatments, a score index based on the comparison of the global photos taken at the beginning (T0) and at the end (T24) of the treatment, was used. The results showed that only 38% of patients treated with Serenoa repens had an increase in hair growth, while 68% of those treated with finasteride noted an improvement. Moreover finasteride was more effective for more than half of the patients (33 of 50, i.e. 66%), with level II and III alopecia. We can summarize our results by observing that Serenoa repens could lead to an improvement of androgenetic alopecia, while finasteride confirmed its efficacy. We also clinically observed, that finasteride acts in both the front area and the vertex, while Serenoa repens prevalently in the vertex. Obviously other studies will be necessary to clarify the mechanisms that cause the different responses of these two treatments.
PMID: 23298508 [PubMed - indexed for MEDLINE]

[bendeniz]

kadınlarda 3 yıllık dutastreid finanstreid kullanım sonucları
The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH1.
Author information
Abstract
BACKGROUND:
The effectiveness of finasteride and dutasteride in women with androgenetic alopecia has been the subject of debate.
AIM:
To evaluate the effectiveness of finasteride and dutasteride on hair loss in women with androgenetic alopecia over a period of 3 years.
METHODS:
From a database containing systematically retrieved data on 3500 women treated for androgenetic alopecia between 2002 and 2012 with finasteride 1.25 mg or dutasteride 0.15 mg, a random sample stratified for age and type of medication was taken to yield 30 women in two age categories: below and above 50 years, and for both medications. Hair thickness of the three thinnest hairs was measured from standardized microscopic images at three sites of the scalp at the start of the treatment and after 3 years of continuous medication intake. The macroscopic images were evaluated independently by three European dermatologists/hair experts. The diagnostic task was to identify the image displaying superior density of the hair.
RESULTS:
Both age categories showed a statistically significant increase in hair thickness from baseline over the 3-year period for finasteride and dutasteride (signed rank test, P = 0.02). Hair thickness increase was observed in 49 (81.7%) women in the finasteride group and in 50 (83.3%) women in the dutasteride group. On average, the number of post-treatment images rated as displaying superior density was 124 (68.9%) in the finasteride group, and 118 (65.6%) in the dutasteride group. Dutasteride performed statistically significantly better than finasteride in the age category below 50 years at the central and vertex sites of the scalp.
CONCLUSIONS:
Finasteride 1.25 mg and dutasteride 0.15 mg given daily for 3 years effectively increased hair thickness and arrested further deterioration in women with androgenetic alopecia.
PMID: 25382509 [PubMed - in process]

[bendeniz]

BASKA CALISMA MELATONİN CALISMASI !!
Topical melatonin for treatment of androgenetic alopecia.
Fischer TW1, Trüeb RM, Hänggi G, Innocenti M, Elsner P.
Author information
1Department for Dermatology, Allergology and Venereology, University of Lübeck, Lübeck, Germany.
Abstract
BACKGROUND:
In the search for alternative agents to oral finasteride and topical minoxidil for the treatment of androgenetic alopecia (AGA), melatonin, a potent antioxidant and growth modulator, was identified as a promising candidate based on in vitro and in vivo studies.
MATERIALS AND METHODS:
One pharmacodynamic study on topical application of melatonin and four clinical pre-post studies were performed in patients with androgenetic alopecia or general hair loss and evaluated by standardised questionnaires, TrichoScan, 60-second hair count test and hair pull test.
RESULTS:
FIVE CLINICAL STUDIES SHOWED POSITIVE EFFECTS OF A TOPICAL MELATONIN SOLUTION IN THE TREATMENT OF AGA IN MEN AND WOMEN WHILE SHOWING GOOD TOLERABILITY: (1) Pharmacodynamics under once-daily topical application in the evening showed no significant influence on endogenous serum melatonin levels. (2) An observational study involving 30 men and women showed a significant reduction in the degree of severity of alopecia after 30 and 90 days (P < 0.001) based on questionnaires completed by investigators and patients. (3) Using a digital software-supported epiluminescence technique (TrichoScan) in 35 men with AGA, after 3 and 6 months in 54.8% to 58.1% of the patients a significant increase of hair density of 29% and 41%, respectively was measured (M0: 123/cm(2); M3: 159/cm(2); M6: 173/cm(2) (P < 0,001). (4) In 60 men and women with hair loss, a significant reduction in hair loss was observed in women, while hair loss in men remained constant (P < 0.001). (5) In a large, 3-month, multi-center study with more than 1800 volunteers at 200 centers, the percentage of patients with a 2- to 3-fold positive hair-pull test decreased from 61.6% to 7.8%, while the percentage of patients with a negative hair-pull test increased from 12.2.% to 61.5% (P < 0.001). In addition, a decrease in seborrhea and seborrheic dermatitis of the scalp was observed.
CONCLUSIONS:
Since safety and tolerability in all of the studies was good, the topical application of a cosmetic melatonin solution can be considered as a treatment option in androgenetic alopecia.

[bendeniz]

Sonuc bu calismalardan yuzlerce var nerde pubmed doktorlar veri tabaNi sitesinde bizim yolumuzu acacak kelligimizi onleyecek savasimizda yol gosterecek calismalar bunlardir biotiN saw palmetto finanstreid mninoxidil yada tOpikal losyonlarimiz BİTKİLER ve daha fazla bilgi almak icin bu sekilde ingilizce calismalari cevirip siteye koysak asil ozaman bişey yapmis olurz yoksa yok teyze kizi deDİki at puskulu kayinco dediki kurbaga bacagi saca iyiymiş sohbetinbden öte gecmez saclar gider gider gider gider....

[Tıbbiyeli]

Günlük 10 mg finasterid nedir arkadaş el insaf ya Adamlara 2 yıl boyunca 10 mg içirmişler